Annual Cash & Cash Equivalents
$1.40 M
-$693.00 K-33.09%
31 December 2023
Summary:
XTL Biopharmaceuticals annual cash & cash equivalents is currently $1.40 million, with the most recent change of -$693.00 thousand (-33.09%) on 31 December 2023. During the last 3 years, it has fallen by -$2.23 million (-61.42%). XTLB annual cash & cash equivalents is now -89.51% below its all-time high of $13.36 million, reached on 31 December 2005.XTLB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.07 M
-$333.00 K-23.77%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly cash and cash equivalents is currently $1.07 million, with the most recent change of -$333.00 thousand (-23.77%) on 31 March 2024. Over the past year, it has dropped by -$389.00 thousand (-26.70%). XTLB quarterly cash and cash equivalents is now -96.68% below its all-time high of $32.17 million, reached on 30 June 2006.XTLB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.1% | -26.7% |
| 3 y3 years | -61.4% | -64.5% |
| 5 y5 years | -57.0% | -77.0% |
XTLB Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -61.4% | at low | -64.5% | at low |
| 5 y | 5 years | -68.5% | at low | -77.0% | at low |
| alltime | all time | -89.5% | +240.1% | -96.7% | +679.6% |
XTL Biopharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $1.07 M(-23.8%) |
| Dec 2023 | $1.40 M(-33.1%) | $1.40 M(-3.8%) |
| Sept 2023 | - | $1.46 M(-8.3%) |
| June 2023 | - | $1.59 M(-16.5%) |
| Mar 2023 | - | $1.90 M(-9.1%) |
| Dec 2022 | $2.09 M(-29.5%) | $2.09 M(-5.9%) |
| Sept 2022 | - | $2.23 M(-5.1%) |
| June 2022 | - | $2.35 M(-16.0%) |
| Mar 2022 | - | $2.79 M(-6.0%) |
| Dec 2021 | $2.97 M(-18.2%) | $2.97 M(-1.4%) |
| Sept 2021 | - | $3.01 M(+3.2%) |
| June 2021 | - | $2.92 M(-14.0%) |
| Mar 2021 | - | $3.39 M(-6.5%) |
| Dec 2020 | $3.63 M(-18.5%) | $3.63 M(-3.2%) |
| Sept 2020 | - | $3.75 M(-6.8%) |
| June 2020 | - | $4.03 M(-5.4%) |
| Mar 2020 | - | $4.26 M(-4.4%) |
| Dec 2019 | $4.46 M(+36.9%) | $4.46 M(-4.0%) |
| Sept 2019 | - | $4.64 M(-2.5%) |
| June 2019 | - | $4.76 M(-6.0%) |
| Mar 2019 | - | $5.06 M(+55.5%) |
| Dec 2018 | $3.25 M(-1.0%) | $3.25 M(+200.3%) |
| Sept 2018 | - | $1.08 M(-4.5%) |
| June 2018 | - | $1.14 M(+11.3%) |
| Mar 2018 | - | $1.02 M(-69.0%) |
| Dec 2017 | $3.29 M(+62.9%) | $3.29 M(-45.9%) |
| Sept 2017 | - | $6.08 M(-3.8%) |
| June 2017 | - | $6.33 M(-6.4%) |
| Mar 2017 | - | $6.75 M(+234.6%) |
| Dec 2016 | $2.02 M(-47.1%) | $2.02 M(-13.0%) |
| Sept 2016 | - | $2.32 M(-10.9%) |
| June 2016 | - | $2.60 M(-16.2%) |
| Mar 2016 | - | $3.11 M(-18.5%) |
| Dec 2015 | $3.82 M | $3.82 M(-11.2%) |
| Sept 2015 | - | $4.30 M(-10.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | - | $4.82 M(+175.0%) |
| Mar 2015 | - | $1.75 M(-18.8%) |
| Dec 2014 | $2.16 M(-25.2%) | $2.16 M(-8.6%) |
| Sept 2014 | - | $2.36 M(-11.8%) |
| June 2014 | - | $2.68 M(+3.1%) |
| Mar 2014 | - | $2.60 M(-10.1%) |
| Dec 2013 | $2.89 M(+70.2%) | $2.89 M(-30.3%) |
| Sept 2013 | - | $4.14 M(+316.5%) |
| June 2013 | - | $995.00 K(-40.4%) |
| Mar 2013 | - | $1.67 M(-1.6%) |
| Dec 2012 | $1.70 M(+13.4%) | $1.70 M(+81.6%) |
| Sept 2012 | - | $934.00 K(-34.2%) |
| June 2012 | - | $1.42 M(-63.9%) |
| Mar 2012 | - | $3.93 M(+163.1%) |
| Dec 2011 | $1.50 M(+40.2%) | $1.50 M(+647.5%) |
| Sept 2011 | - | $200.00 K(-21.9%) |
| June 2011 | - | $256.00 K(-55.7%) |
| Mar 2011 | - | $578.00 K(-45.8%) |
| Dec 2010 | $1.07 M(+158.7%) | $1.07 M(-22.6%) |
| Sept 2010 | - | $1.38 M(+905.1%) |
| June 2010 | - | $137.00 K(-45.4%) |
| Mar 2010 | - | $251.00 K(-39.1%) |
| Dec 2009 | $412.00 K(-85.9%) | $412.00 K(-35.6%) |
| Sept 2009 | - | $640.00 K(-78.1%) |
| Dec 2008 | $2.92 M(+23.0%) | $2.92 M(-5.3%) |
| June 2008 | - | $3.09 M(+29.9%) |
| Dec 2007 | $2.38 M(-46.0%) | $2.38 M(-3.0%) |
| June 2007 | - | $2.45 M(-44.3%) |
| Dec 2006 | $4.40 M(-67.1%) | $4.40 M(-86.3%) |
| June 2006 | - | $32.17 M(+140.8%) |
| Dec 2005 | $13.36 M(+4.5%) | $13.36 M(+169.0%) |
| June 2005 | - | $4.97 M(-61.2%) |
| Dec 2004 | $12.79 M(+205.6%) | $12.79 M(+63.1%) |
| June 2004 | - | $7.84 M |
| Dec 2003 | $4.18 M | - |
FAQ
- What is XTL Biopharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual cash & cash equivalents year-on-year change?
- What is XTL Biopharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is XTL Biopharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of XTLB is $1.40 M
What is the all time high annual cash & cash equivalents for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual cash & cash equivalents is $13.36 M
What is XTL Biopharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, XTLB annual cash & cash equivalents has changed by -$693.00 K (-33.09%)
What is XTL Biopharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of XTLB is $1.07 M
What is the all time high quarterly cash and cash equivalents for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly cash and cash equivalents is $32.17 M
What is XTL Biopharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, XTLB quarterly cash and cash equivalents has changed by -$389.00 K (-26.70%)